Co-Diagnostics Inc (HAM:C970)

Q4 2025 Co-Diagnostics Inc Earnings Call Transcript

Mar 31, 2026 / 08:30 PM GMT

Release Date Price: €5.55

Transcript 10-K8-K

Key Points

Positve

Co-Diagnostics Inc (CODX) successfully completed the appeal to have their shares relisted on NASDAQ, indicating a resolution to previous listing challenges.
The company has advanced several key initiatives, including the Coursera joint venture in India, which has established a nationwide commercial presence and cleared 15 PCR tests through India's regulatory pathway.
Co-Diagnostics Inc (CODX) is expanding its international footprint through the COMIRA joint venture with Arabian Eagle, targeting Saudi Arabia and the broader MENA region.
The company is leveraging AI-driven capabilities to enhance innovation, efficiency, and data-driven insights across its platform, which may support predictive insights and improve real-time situational awareness.
Co-Diagnostics Inc (CODX) has strengthened its intellectual property portfolio with international patents, including recent grants in Australia and Japan, supporting its long-term strategy of building a differentiated diagnostics platform.

Negative

Total revenue for 2025 was significantly lower at $0.6 million compared to $3.9 million in 2024, primarily due to decreased grant revenue.
The company reported a net loss of $46.9 million for 2025, an increase from the $37.6 million loss in 2024, driven by a non-cash impairment charge and lower grant revenue.
Operating expenses increased to $50.6 million in 2025 from $43.0 million in 2024, largely due to a non-cash impairment charge related to in-process research and development intangible assets.
Product revenue decreased to $0.4 million in 2025 from $0.8 million in 2024, reflecting limited commercial activity during the period.
The company ended the year with $11.9 million in cash equivalents and marketable investment securities, down from $29.7 million at the end of 2024, indicating a decrease in liquidity.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CODX.OQ - Co-Diagnostics Inc
Q4 2025 Co-Diagnostics Inc Earnings Call
Mar 31, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day, everyone, and thank you all for joining today's Co-Diagnostics, Inc. Full year 2025 earnings webcast. As a reminder, all phone participants are in a listen-only mode, but later you will be provided with the opportunity to ask a question during our question-and-answer session.

As a reminder, today's session is being recorded. And it is now my pleasure to turn the floor over to Head of Investor Relations, Mr. Andrew Benson. Please go ahead, sir.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good afternoon, everyone.

Thank you all for participating in today

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.